Soft Tissue Sarcoma Market Report 2026

The soft tissue sarcoma market size has grown strongly in recent years. It will grow from $3.41 billion in 2025 to $3.7 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to improved cancer diagnostics, oncology research funding, awareness of rare cancers, chemotherapy availability, surgical advancements.

The soft tissue sarcoma market size is expected to see strong growth in the next few years. It will grow to $5.17 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to novel drug approvals, immunotherapy expansion, molecular testing growth, personalized treatment demand, oncology infrastructure development. Major trends in the forecast period include growth of targeted therapy use, increased genetic profiling, expansion of combination regimens, rising clinical trial enrollment, multidisciplinary care adoption.

The rising incidence of cancer is expected to drive the growth of the soft tissue sarcoma market in the coming years. Cancer is a broad group of diseases that can occur in any organ or tissue when abnormal cells grow uncontrollably, breach their usual boundaries, and either spread to other organs or invade surrounding tissues. The increasing number of cancer cases creates greater demand for diagnostic procedures, treatment options, and supportive care tailored to the needs of patients with various types of cancer or sarcomas, thereby boosting the soft tissue sarcoma market. For example, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2023, approximately 165,000 Australians were newly diagnosed with cancer, averaging over 450 cases per day, with males accounting for about 55% of these diagnoses. Consequently, the surge in cancer incidence is driving the growth of the soft tissue sarcoma market.

Key players in the soft tissue sarcoma market are focusing on developing innovative products to strengthen their market presence. For instance, in November 2023, Mercy, a US-based not-for-profit Catholic healthcare organization, launched an AI-driven texting program called The Chen Chemotherapy Model to proactively prevent chemotherapy-related hospitalizations. This program uses a smart texting platform that sends daily messages to chemotherapy patients seven days a week, excluding weekends and holidays. The messages include a list of symptoms such as diarrhea, pain, fever, fatigue, nausea or vomiting, or no symptoms. Patients can select and rate their symptoms, and based on their responses, the information may be escalated to their healthcare provider. The program aims to identify potential issues early and intervene before symptoms worsen, showcasing Mercy’s commitment to leveraging technology for enhanced patient care in chemotherapy.

In February 2025, GSK Plc, a UK-based healthcare company, acquired IDRx, Inc., for an undisclosed amount. This acquisition is intended to strengthen GSK’s specialty pharmaceuticals portfolio, accelerate innovation, enhance its pipeline of novel therapies, and expand capabilities in targeted drug development. IDRx, Inc., is a US-based biopharmaceutical company focused on the discovery and development of precision medicines for complex diseases.

Major companies operating in the soft tissue sarcoma market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol Myers Squibb, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Lupin Ltd., Philogen S.p.A., Taiho Pharmaceutical Co.Ltd., Nanobiotix S.A.

North America was the largest region in the soft tissue sarcoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the soft tissue sarcoma market report during the forecast period. The regions covered in the soft tissue sarcoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the soft tissue sarcoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have raised costs in the soft tissue sarcoma market by increasing prices for imported chemotherapy drugs, targeted therapies, radiation equipment, and oncology biologics. Hospitals and specialty centers in Asia-Pacific and emerging markets are particularly affected due to reliance on global pharmaceutical suppliers. These cost pressures can limit access to advanced treatment regimens. At the same time, tariffs are promoting domestic oncology drug manufacturing, strengthening long-term treatment availability.

The soft tissue sarcoma market research report is one of a series of new reports that provides soft tissue sarcoma market statistics, including soft tissue sarcoma industry global market size, regional shares, competitors with a soft tissue sarcoma market share, detailed soft tissue sarcoma market segments, market trends and opportunities, and any further data you may need to thrive in the soft tissue sarcoma industry. This soft tissue sarcoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Soft tissue sarcoma is a disease in which cancer cells develop in the soft tissues of the body and can be diagnosed using biopsy techniques. It commonly occurs in tissues such as blood vessels, muscles, nerves, and fat.

The primary treatment options for soft tissue sarcoma include targeted therapy, chemotherapy, anti-angiogenesis drugs, radiation therapy, and others. Targeted therapy involves treatments that specifically focus on the genes, proteins, or tissue environment that support cancer growth and survival, preventing cancer cells from proliferating, dividing, and forming new cells. These treatments can be administered through various routes, including oral and parenteral methods. They are utilized by end users such as hospitals, homecare providers, specialty centers, and other healthcare settings.

The soft tissue sarcoma includes revenues earned by entities by immunotherapy, hormone therapy, photodynamic therapy, and stem cell transplant. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.